AIG Hospitals Hyderabad Launches Gut Microbiome Therapeutics and Pill Lab

AIG Hospitals in Hyderabad launched a dedicated Gut Microbiome Therapeutics and Pill Lab on Saturday, August 29, to study the therapeutic potential of the human gut microbiome. The newly established facility will focus initially on inflammatory bowel disease (IBD), including conditions such as ulcerative colitis and Crohn’s disease.

The research platform will work on developing oral microbiome capsule formulations using scientifically screened donor material. The complete process at the facility covers microbiome profiling, controlled sample processing, preservation, capsule formulation, strict quality and safety checks, and formal clinical research protocols.

Hospital authorities clarified that the microbiome pill being developed at the facility is intended strictly for research purposes. The capsules will be utilised solely as part of approved clinical research programmes rather than commercial or routine medical treatments.

The gut microbiome, which consists of trillions of microorganisms living inside the human digestive tract, is subject to growing medical study for its critical role in immunity, inflammation, metabolism, gut-barrier function, and patient response to various treatments. Medical science has identified that changes in microbial balance, known as dysbiosis, are closely associated with various gastrointestinal and systemic illnesses, particularly IBD.

AIG Hospitals Chairman D. Nageshwar Reddy noted that restoring a healthier microbial ecosystem holds significant potential for treating chronic inflammatory conditions, particularly in cases where standard conventional therapies do not fully resolve the underlying biological imbalance.

Rupa Banerjee, Director of the IBD Centre at the hospital, explained that the facility has been built with an emphasis on scientific quality, donor safety, standardised workflows, traceability, and clinical relevance. She stated that every single stage, from the initial donor screening to final capsule formulation and ongoing patient monitoring, would be executed under defined protocols.